Clinical Trials

  • Paddy Farrington
  • Elizabeth Miller
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 4)

Abstract

The transition from laboratory testing to evaluation in humans marks an important stage in vaccine development. Questions about safety and benefit to the patient and to the community may raise difficult ethical issues, whereas the inherent variability of human responses must be taken into account to obtain valid estimates of vaccine effect. This latter requirement explains why a coherent statistical framework for the design, analysis, and interpretation of clinical trials is regarded as essential today. A vast body of experience and methodology has been developed since the 1940s, when the scientific method was first applied systematically to the evaluation of vaccines. A striking feature of clinical trial research is its broad collaborative nature, involving laboratory, epidemiological, clinical, and statistical skills. As a consequence, rather than attempt to describe in detail the planning and conduct of clinical trials, this chapter will review the broad principles and stages involved in evaluating vaccines in humans, using examples from the literature. Details of methodological and other issues of particular relevance to vaccine evaluation are provided in Section 3.

Keywords

Placebo Toxicity Polysaccharide Malaria Meningitis 

References

  1. 1.
    Byar, D. P., Schoenfeld, D. A., Green, S. B., Amato, D. A., Davis, R., DeGruttda, V., et al. (1990) Design considerations for AIDS trials. N Engl. J. Med. 323, 1343–1348.PubMedCrossRefGoogle Scholar
  2. 2.
    Bellanti, J. A., Zeligs, B. J., Vetro, S., Pung, Y.-H., Luccioli, S., Malvasic, M. J., Hook, A. M, Ubertini, T. R., Vanni, R., and Nencioni, L. (1993) Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate. Vaccine 11, 587–590.PubMedCrossRefGoogle Scholar
  3. 3.
    Costantino, P., Viti, S., Audino, P., Velmonte, M. A., Nencioni, L, and Rappuoli, R. (1992) Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691–698.PubMedCrossRefGoogle Scholar
  4. 4.
    Gold, R., Leplow, M. L., Goldchneider, I., Draper, T. F., and Gotschlich, E (1979) Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children J. Infect. Dis. 140, 690–697.PubMedGoogle Scholar
  5. 5.
    Rutter, D. A., Ashworth, L. A. E., Day, A., Funnell, S., Lovell, F., and Robinson, A. (1988) Trial of a new acellular pertussis vaccine in healthy adult volunteers Vaccine 6, 29–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Bock, H L, Klockmann, U., Jungst, C., Schindel-Kunzel, F., Theobald, K., and Zerban, R. (1990) A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study. Vaccine 8, 22–24PubMedCrossRefGoogle Scholar
  7. 7.
    Picard, O, Giral, P., Defer, M. C., Fouchard, M., Morel, M, Meyohas, M. C, et al. (1990) AIDS vaccine therapy: phase I trial (letter). Lancet 336, 179.PubMedCrossRefGoogle Scholar
  8. 8.
    Scheifele, D., Bjornson, G., Barreto, L, Meekison, W., and Guasparini, R. (1992) Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month old children, including comparison of arm versus thigh injection. Vaccine 10, 455–460.PubMedCrossRefGoogle Scholar
  9. 9.
    Miller, E, Ashworth, L A., Robinson, A., Waight, P. A, and Irons, L. I. (1991) Phase II trial of whole-cell pertussis vaccine versus an acellular vaccine. Lancet 337, 70–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Pichichero, M. E., Marsocci, S. M., Francis, A B., Green, J. L., Disney, F A., Rennels, M. B., Lewis, E. D, Sugarman, L., Losonsky, G. A., Zito, E., and Davidson, B. L. (1993) A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants Vaccine 11, 747–753.PubMedCrossRefGoogle Scholar
  11. 11.
    Strauss, S. E., Corey, L., Burke, R. L., Savarese, B., Barnum, G., Krause, P. R., Kost, R. G., Meir, J. L., Sekulovich, R., Adair, S. F., and Dekker, C. L. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343, 1460–1463.CrossRefGoogle Scholar
  12. 12.
    Valero, M. V., Amador, L. R., Galindo, C., Figueroa, J., Bello, M. S., Murillo, L. A, et al (1993) Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705–710.PubMedCrossRefGoogle Scholar
  13. 13.
    Sempertegui, F., Estrella B, Moscoso, J, Piedrahita, L, Hernandez, D., Gaybor, J., et al. (1994) Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12, 337–342.PubMedCrossRefGoogle Scholar
  14. 14.
    Hall, A. J. and Aaby, P. (1990) Tropical trials and tribulations. Int. J. Epidemiol. 19, 777–781.PubMedCrossRefGoogle Scholar
  15. 15.
    Francis, T, Korns, R. F., Voight, T., Boisen, M., Hemphill, F. M., Napier, J. A., and Tolchinsky, E. (1955) An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health Part 2 45, 1–63.Google Scholar
  16. 16.
    Fine, P. E M. and Clarkson, J. A. (1987) Reflections on the efficacy of pertussis vaccines. Rev. Infect. Dis. 9, 866–883.PubMedCrossRefGoogle Scholar
  17. 17.
    Vesikari, T. (1993) Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine 11, 255–261.PubMedCrossRefGoogle Scholar
  18. 18.
    Medical Research Council (1951) The prevention of whooping-cough by vaccination: a Medical Research Council investigation. Br. Med. J. June 30, 1463–1471.Google Scholar
  19. 19.
    Farrington, C. P. (1990) Quantifying misclassification bias in cohort studies of vaccine efficacy. Stat Med. 9, 1327–1337.PubMedCrossRefGoogle Scholar
  20. 20.
    PHLS Epidemiological Research Laboratory and 21 Area Health Authorities (1982) Efficacy of pertussis vaccination in England. Br. Med. J. 285, 357–359.CrossRefGoogle Scholar
  21. 21.
    Storsaeter, J., Hallander, H., Farrington, C. P., Olin, P., Mollby, R, and Miller, E. (1990) Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8, 457–461.PubMedCrossRefGoogle Scholar
  22. 22.
    Ad-Hoc Group for the Study of Pertussis Vaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet April 30, 955–960.Google Scholar
  23. 23.
    Volberding, P. A, Lagakos, S. W., Koch, M A., Pettinelli, C., Myers, M W., Booth, D. K., et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl J. Med. 322, 941–949.PubMedCrossRefGoogle Scholar
  24. 24.
    Simanjuntak, C. H., Paleologo, F., Punjabi, N. H., Darmowigoto, R., Soeprawoto, Totosuderjo, H., Haryanto, P., Suprijanto, E., Witham, N. D., and Hoffman, S. L. (1991) Oral immunisation against typhoid fever in Indonesia with Ty2la vaccine Lancet 338, 1055–1059.PubMedCrossRefGoogle Scholar
  25. 25.
    Storsaeter, J., Olin, P., Renemar, B., Lagergard, T, Norberg, R., Romanus, V, Tiru, M., et al. (1988) Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect. Dis. J. 7, 637–645PubMedCrossRefGoogle Scholar
  26. 26.
    Garenne, M., Leroy, O., Beau, J.-P., and Sene, I. (1991) Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 338, 903–907.PubMedCrossRefGoogle Scholar
  27. 27.
    Medical Research Council Whooping Cough Immunisation Committee (1956) Vaccination against whooping cough: relation between protection and results of laboratory tests Br. Med J. 2, 454–462.CrossRefGoogle Scholar
  28. 28.
    Orenstein, W. A., Bernier, R. H., Dondero, T. J., Hinman, A. R., Marks, J. S., Bart, K. J., and Sirotkin, B. (1985) Field evaluation of vaccine efficacy. WHO Bulletin 63, 1055–1068.Google Scholar
  29. 29.
    Begg, N. and Miller, E. (1990) Role of epidemiology in vaccine policy. Vaccine 8, 180–189.PubMedCrossRefGoogle Scholar
  30. 30.
    PHLS Whooping-Cough Committee and Working Party (1973) Efficacy of whooping-cough vaccines used in the United Kingdom before 1968. Br. Med. J. Feb. 3, 259–262.Google Scholar
  31. 31.
    Miller, E., Goldacre, M., Pugh, S., Colville, A., Farrington, P., Flower, A., Nash, J., MacFarlane, L., and Tettmar, R. (1993) Risk of aseptic meningitis after measles mumps and rubella vaccine in UK children. Lancet 341, 979–982.PubMedCrossRefGoogle Scholar
  32. 32.
    Farrington, P., Pugh, S., Colville, A., Flower, A., Nash, J., Morgan-Capner, P., et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345, 567–569.PubMedCrossRefGoogle Scholar
  33. 33.
    Diamond, A L and Laurence, D. R (1983) Compensation and drug trials (Commentary) Br Med. J. 287, 676–677.CrossRefGoogle Scholar
  34. 34.
    Association of the British Pharmaceutical Industry (1983) Compensation and drug trials. Br. Med. J. 287, 675.CrossRefGoogle Scholar
  35. 35.
    Pocock, S.J. (1983) Clinical Trials A Practical Approach. Wiley, Chichester.Google Scholar
  36. 36.
    Farrington, C. P. and Manning, G. (1990) Test statistics and sample size formulae for comparative binomial trials with null hypotheses of non-zero risk difference or non-unity relative risk. Stat. Med. 9, 1447–1454.PubMedCrossRefGoogle Scholar
  37. 37.
    Machin, D. and Campbell, M. J. (1987) Statistical Tables for the Design of Clinical Trials Blackwell Scientific, Oxford.Google Scholar
  38. 38.
    Altman, D. G. and Dore, C. J. (1990) Randomisation and baselie comparisons in clinical trials. Lancet 335, 149–153.PubMedCrossRefGoogle Scholar
  39. 39.
    Levine, M. M., Fereccio, C., Cryz, S., and Ortiz, E. (1990) Comparison of entericcoated capsules and liquid formulation of Ty2la typhoid vaccine in randomised controlled field trial. Lancet 336, 891–894.PubMedCrossRefGoogle Scholar
  40. 40.
    Newell, D. J. (1992) Intention-to-treat analysis: implications for quantitative and qualitative research. Int. J. Epidemiol. 21, 837–841.PubMedCrossRefGoogle Scholar
  41. 41.
    Farrington, C. P. (1993) Intention-to-treat analysis: implications for quantitative and qualitative research (letter). Int. J. Epidemiol. 22, 566.PubMedCrossRefGoogle Scholar
  42. 42.
    Medical Research Council (1966) Vaccination against measles: a clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Br. Med. J. February 19, 441–446.Google Scholar
  43. 43.
    Clemens, J. D., Sack, D. A., Harris, J. R., Chakraborty, J., Khan, M. R., Stanton, B. F., Kay, B. A., Khan, M. U., Yunus, M., Atkinson, W., Svennerholm, A. M., and Holgren, J. (1986) Field trials of oral cholera vaccines in Bangladesh. Lancet July 19, 124–127.Google Scholar

Copyright information

© Humana Press Inc, Totowa, NJ 1996

Authors and Affiliations

  • Paddy Farrington
    • 1
  • Elizabeth Miller
    • 1
  1. 1.Statistics UnitPHLS Communicable Disease Surveillance CentreLondonUK

Personalised recommendations